Page 1 - Title Page
Dear Colleague, This is the second mailing of antiretroviral therapy with protease inhibitors, a joint effort of The Minority AIDS Council, Project Inform, AIDS Treatment Data Network, and Gay Men's Health Crisis. This packet contains updated information about the use of protease inhibitors in combination with nucleoside analogs. Currently there are four protease inhibitors: Crixivan (indinavir), Invirase (saquinavir), Norvir (ritonavir), and Nelfinavir (viracept), which are used in combination therapy with five different nucleoside analogs: AZT, 3TC, d4T, ddC, ddl and with two non-nucleoside reverse transcriptase inhibitors: Viramune (nevirapine) and Rescriptor (delavirdine). W. do know that antiretroviral therapy with protease inhibitors is saving lives, but we still do not know how to use these drugs most effectively. We do not yet know when is the best time to start therapy, which combinations are best to use first, how long the effect of these drugs can last, and what are the long-term side effects. Many people are working very hard to answer all of these questions through continued clinical research, but this takes time. Meanwhile, people with HIV are faced with having to make treatment decisions today. Our organizations are collaborating in sending you this packet of treatment information so that you and your doctor can make the best-informed decision about your treatment. We feel that the information we are providing you is very important and we are committed to doing everything we can to keep you informed. We encourage you to please make as many copies of this packet as you need. If you have any suggestions or comments on this packet, please call any of our organizations. Thank you for your support. Yours truly, Moises Agosto-National Minority AIDS Council Pablo Colon-Gay Men's Health Crisis Martin Delaney-Project Inform Ken Fornataro-AIDS Treatment Data Network 5571095.0291.005